Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FFS
When it comes to evaluating short positions, both the days to cover and the percentage of shares shorted (short interest) are important metrics, but they provide different insights.
Days to cover is a measure of the potential duration of a short squeeze, calculated by dividing the current short interest by the average daily trading volume. A higher days to cover ratio indicates it would take longer for short sellers to cover their positions, potentially exacerbating a short squeeze if one were to occur.
On the other hand, the percentage of shares shorted (short interest) represents the overall bearish sentiment and level of short selling activity in a stock. A high short interest percentage suggests that many investors are betting against the stock and expect the price to decline.
While both metrics are valuable, the percentage of shares shorted is generally considered more important for the following reasons:
It directly quantifies the level of short selling activity and bearish sentiment, which can be a leading indicator of potential price movements.
A high short interest percentage increases the risk of a short squeeze, as more short sellers may be forced to cover their positions if the stock price rises unexpectedly.
The days to cover ratio can be skewed by low trading volume, making it less reliable in thinly traded stocks.
Therefore, while days to cover provides insight into the potential duration of a short squeeze, the percentage of shares shorted is a more fundamental metric that directly reflects the overall short selling pressure and bearish sentiment towards a stock.
Investors typically prioritize monitoring the short interest percentage, as it is a better indicator of the potential for a significant price move, either up or down.
We ended the first quarter with a cash position of $308 million, marking a stable cash position over 7 quarters. Importantly, we also secured shareholder approval for our share repurchase program of up to $50 million. Our next step is to secure U.K. High Court approval and the share repurchases are anticipated to begin in the second quarter.
The key though is the “days to cover” (which has double over the past year).
This is due in part to both an increase of shorts, and a substantial decrease in average volume. 12 days is an attractive squeeze number.
It doesn’t take a lot of effort (volume) to ignite a squeeze. Once shorts are on the run, the stock gains attraction by virtue of its deep “fallen angel” reversal TA characteristics, making it very easy to affect a major trend reversal/run up.
Thanks for posting Lizzy. Glad that after Bhatt mentions mixed omegas that he then follows up to say that evidence for EPA is clear. Would love to have Nissen tied up in a chair and force feed him this clip on a reel.
JR, I really dont know what to think of this post ?
-----------------------------------------------------------------
Do you 'at all' - understand the Reduce-It trial - based on Vascepa - times 8 purified EPA ?
How can you seriously talk about general Omega 3 oil products in this context ?
------------------------------
You say you own 200k AMRN shares - representing an FDA approved medicine for greatly reducing risk for CDV patients !
I fail to understand how you can promote the endless number of ordinary OTC fish-oil products on the internet - being invested this BIG in AMRN and Vascepa ?
I haven't been checking in so I apologize if this has already been posted
#cardiology #cardiotwitter #cardioX #prevention @escardio https://t.co/DXCqkncUyo
— Dr. Deepak L. Bhatt (@DLBHATTMD) May 14, 2024
AMRN unlikely to be a short squeeze candidate with this low amount of short interest
Short % As of Apr-30-2024. 4%
Shares short16.18 (M)+0.34 (M)
Days to cover12.88+0.34
JMO ...
Kiwi
You need very high short positions held by master of the universe hedge fund types, to effect a GME type short squeeze.
Kiwi
True. Although there IS efficacy with mixed Omega-3's, just not necessarily for CV disease (other than Trigs).
Which is why Lovaza is so confusing. People (generally?) take it for heart health. But it misses the mark.
I have even tried educating Rhonda on the benefits of EPA-only, but she is not promoting Omega-3's strictly for CV health. She's read REDUCE-It, etc. So that's another challenge - there are benefits to Omega-3's beyond just CV health, so a lot of health professionals aren't necessarily sold on strictly EPA.
I wonder if that point is across. Docs prescribing Lovaza, docs telling people to just go out and buy omega-3’s, a whole bunch of people buying omega-3’s from the supplement industry without talking to their docs about it. Amarin needs to get people to understand the differentiation between V all those mixed omegas.
There was a recent poster yes but also not seeing an endorsement either. If any of you young bucks know how to get more visibility or how to promote that dudes post, that would be a start. I’m not reddit friendly. Someone needs to give that page a full view of why this would be perfect meme stock setup
Sleven, Seems like it all about a sarcastic comment on YH conversations AMRN:
rick
22 hours ago
Rumor is Roaring Kitty interested in Amrn
Share
When it happens on low volume, it usually doesn't mean much at all.
I follow Rhonda Patrick (Found My Fitness), who is a big supporter of Omega-3's (though not specifically EPA), and she made a statement in one of her podcasts that was simple but to the point..."Omega-3s broadly seem to have pharmacological potential similar to that of a drug, but a risk profile more akin to a nutrient."
It's too bad that Amarin can't get this point across.
It’s probablyBS. Yahoo is not the best source of facts.
Retired, I can't find any evidence that Roaring Kitty has endorsed Amarin.
Sleven,
Is that like saying Blue Horse Shoe likes Annicot Steel?
Yahoo has a post that Roaring Kitty likes Amarin.
You are correct Kiwi. Even if that is not the reason for today's move, one would think that the price should move up in anticipation of the buyback.
Capt...The study on cervical cancer indicates..."a high level of plasma EPA was independently correlated with an increased incidence of CR(i.e.complete response after CCRT(i.e.concurrent chemoradiotherapy (odds ratio (OR), 0.980; 95% CI(i.e.confidence interval), 0.962-0.999, P=0.038). With a median follow-up of 41.3 months.
For us non GYN docs, who may be puzzled by the abbreviations in this important article ...The complete response is AMAZING and further emphasizes the fact that many cancer patients need EPA as a part of their treatment.
Newman. My guess is that its positioning in advance of the expected UK approval of the share buyback
Share buybacks can positively impact a company's stock price through several mechanisms:
Increased earnings per share (EPS): By reducing the number of outstanding shares, the company's earnings are divided among fewer shares, resulting in a higher EPS. A higher EPS can make the stock more attractive to investors and drive up the share price.
Increased demand: When a company repurchases its own shares, it creates additional demand for those shares in the market, which can lead to an increase in the stock price.
Signaling effect: Share buybacks can be interpreted by investors as a signal that the company's management believes the stock is undervalued. This positive signal can boost investor confidence and drive up the stock price.
Increased ownership stake: As the number of outstanding shares decreases, the remaining shareholders' ownership stake in the company increases proportionally. This can make the stock more valuable to investors.
Improved financial metrics:
Share buybacks can improve financial metrics such as return on equity (ROE) and return on assets (ROA), making the company more attractive to investors and potentially increasing the stock price.
When it happens on low volume, it usually doesn't mean much at all. Makes it more likely tomorrow that it drops the same amount it rose today, or even later today.
wtf is goin on? why it is up so guick?
Inflammation! A big driver for all kinds of diseases and conditions. Heart Disease and Cancer make up 50-60% of all cause mortality worldwide. Looks like EPA fights both! Yep, it’s the EPA STUPID!
What post are you responding to or what drug are you talking about?
DealFlow’s “The Activist Investor Conference" held on March 21, 2024 in New York City.
Patrice Bonofiglio, President Sarissa Capital, made a presentation in the above conference under the theme:
"Defining the Spectrum of Success in Shareholder Activism:"
· Navigating a retail shareholder base
· Reinserting the “G” in ESG in 2024
· Inflection points for successful shareholder activism
Patrice was joined by Phillip Goldstein, Founder and CEO of Bulldog Investors to discuss Good, Bad and Ugly - Defining Shareholder Activism Success and Failure + When and how activism goes wrong and how to move forward + Ways shareholder activism helps propel stagnant companies into a brighter future + Case studies and situational analysis that help drive better decisions.
To get the script of the presentation one must pourchasse the scripts of the entire conference from DealFolw events for $495.
This should not be via a prescription anymore.
Thanks Tats. I was looking at it wrong.
Nuke,
Great Timing. Here's hoping your sister-in-law responds well to the treatment, and gives that article to her oncologist.
Dave
Thanks ABC; My sister-in-law was prognosed with cervical cancer. Her initial appointment for the insertion of the dosing apparatus is this morning. I'll send her this article. Thank you.
Epadel 900 has a much higher dosage does it not? Copied from your link.
Sorry, will try the link again.
Dave
EPA and Cervical Squamous Cell Cancer Study. EPA and The Prognosis and Response to Chemoradiotherapy. An initial report on a small study out of China. (The Title of the report mentions Omega-3, but the report itself focuses on EPA)
Med Terms: OS is Overall Survival; PFS is Progression Free Survival
Dave
Always amazed when I have talked to medical practitioners and the ignorance about Vascepa.
The mineral oil campaign waged a few years ago by people with conflicting interest did a lot of damage. Amarin should have gone hard with cease and desist letters that demanded retractions in print.
.
Includes my primary care physician.
Thanks North40k. I will read those in a bit and refrain for opining until then.
We have got to get Nunavut on board. I think every single one of those 40,586 people there need Vascepa. Freezing your ass off is very inflammatory.
JR, Ok - fair enough. We can agree on SP of AMRN will (has to) improve before we leave 2024 ✌️
Patrice Bonfiglio, President at Sarissa Capital Management LP
https://www.linkedin.com/posts/missionmattersbusiness_adamtorres-spotify-itunes-activity-7183819370802917376-2O7Y?utm_source=share&utm_medium=member_ios
Jasbg, give it a rest. I was only agreeing that it's possible that this would be a need for funds for him (as a follow-up to my suggestion that Sarissa has a lot of cash to spend). I'm not interested in his personal life.
Freedom of speech doesn’t mean anything unless you’re able to hear/read things you don’t like.
Nope. I'm gonna comment about whatever I want whenever I want. Including your patron saint Denner's personal life.
JR, Of course - you would have to comment on this deeply negative and offensive nonsense - on Denners personal life.
----------------------------------------------
200k shares! A bit weird you dont defend / trust people behind future of Amarin more ??
Tats...Let's refrain from making unnecessary, unproductive comments about Denner's personal life.
Nice. Thanks Dogn. I was trying to find an English version but couldn't find it.
Thanks for that.
Yeah, but not sure how much of his funds were owned by him personally (versus his investors). But that's a valid point.
giant pile of cash
Yes, Springer is a major publisher in all areas of science and engineering
https://group.springernature.com/gp/group/about-us/health-business
One could only hope. Their original cost basis total was over $110M when they purchased their initial 24M shares and then they have purchased more since getting the new board members. So, they could really buy some 'on the cheap' along with the share BB. Those acts alone could serve to get some additional institutional ownership that we need. So many positive opportunities ahead for 2024 and 2025.
Great news for the heart disease and obesity industrial complexes!
https://www.nbcnews.com/health/heart-health/adults-us-heart-diabetes-syndrome-risk-research-rcna151215
Followers
|
1107
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
428665
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators ziploc_1 zmanindc golf stud Number sleven |
AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote
Y! Finance AMRN Landing Page
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |